PART I Item 1. B usiness. Overview We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. Haduvio acts on the cough reflex arc both centrally and periphe...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001193125-26-110783 | EDGAR | 99K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-041194 | EDGAR | — |
| 2024-03-20 | 2023-12-31 | 0000950170-24-034167 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008472 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001564590-22-010875 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015506 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-010996 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-280166 | EDGAR | 70K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105066 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067011 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122355 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093983 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-054489 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062063 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041318 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021240 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001564590-22-037385 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001564590-22-029142 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001564590-22-019895 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-17 | 0001193125-26-110767 | EDGAR | 2K words |
| 2026-03-09 | 0001193125-26-098676 | EDGAR | — |
| 2025-12-05 | 0001193125-25-308769 | EDGAR | — |
| 2025-11-13 | 0001193125-25-280149 | EDGAR | — |
| 2025-08-20 | 0001563880-25-000005 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105011 | EDGAR | — |
| 2025-06-17 | 0000950170-25-087486 | EDGAR | — |
| 2025-06-04 | 0001193125-25-134913 | EDGAR | — |
| 2025-06-02 | 0001193125-25-133273 | EDGAR | — |
| 2025-06-02 | 0001193125-25-132890 | EDGAR | — |
128 total filings indexed. 99 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001563880 |
| Ticker | TRVI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.trevitherapeutics.com |
| Listed | 2019-05-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report